BB Biotech investment company returned to profit in the first half of 2017 – and closed a most profitable chapter of its history.
BB Biotech, an investment company based in Schaffhausen, Switzerland, had a profit of 478 million Swiss francs in the first six months of 2017, with 103 million in the second quarter, the company said in a statement today.
Actelion Success Story
The takeover of Swiss biotech giant Actelion by Johnson & Johnson concluded one of the great success stories of BB Biotech. The investment in the Allschwil-based biotech company generated profits of a total 750 million francs over the years.
BB Biotech used the money it received for its stake in Actelion to increase stakes in Alexion, Alder, Avexis, Esperion, Halozyme, Intra-Cellular, Neurocrine Biosciences and Radius Health.
